RXRX / Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates

SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize more_horizontal

Recursion Pharmaceuticals is using a novel and promising approach to drug discovery. Its strategy has produced some candidates, but none yet seems clo more_horizontal

It has multiple programs in its pipeline, which focuses on rare diseases and cancer. Its use of artificial intelligence made the stock a hot buy earli more_horizontal

Recursion Pharmaceuticals has three different business segments that could grow. Its drug development pipeline will take the longest to yield sales. more_horizontal

Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those price more_horizontal

Shares of Recursion Pharmaceuticals Inc. RXRX, +3.30% jumped more than 4% premarket on Thursday after chip giant Nvidia Corp. NVDA, +3.17% on Wednesda more_horizontal

Recursion's pipeline is chasing a handful of relatively small opportunities. Its collaboration with Nvidia will take some time to pay off, assuming it more_horizontal

Chris Gibson, Recursion CEO, joins 'Closing Bell Overtime' to talk drug development, quarterly earnings, tech integration in pharmaceuticals and more. more_horizontal